Warning letter
Uriel Pharmacy, Inc [ARCHIVED]: warning letter of Aug 18, 2011
FDA warning letter 161712 · Minneapolis District Office
Key facts
| Reference number | 161712 |
|---|---|
| Company | Uriel Pharmacy, Inc [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Misbranded/Adulterated |
| Issue date | Aug 18, 2011 |
| Posted date | Aug 18, 2011 |
| Issuing office | Minneapolis District Office |
| Product type | Drugs |
| CFR sections cited | 211.110(a), 211.160(b), 201.5, 210, 211.192, 201.10(c)(4), 211.25(c), 211.94(c), 211.113(b) |
| Inspection city | East Troy |
| Inspection ZIP | 53120 |
| Inspection start date | Oct 18, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: